

**WHIMS Presentation: Steve Rapp, [srapp@wakehealth.edu](mailto:srapp@wakehealth.edu)**

Aladdin Shadyab: Hi Steve. Could you please clarify if WHI is still adjudicating MCI and dementia in women in WHIMS-ECHO? And through what date will WHIMS-ECHO conduct cognitive tests?

Emily Gower: is the LLS overlap the LLS baseline or current live participants?

JoAnn Manson: Could you comment whether missingness during follow up correlates with performance on the most recent cognitive assessments?

Sylvia Smoller: Where is there access too the adjudicated dataset?

cauley: How many deaths have there been?

Katie Stone: What is the best way to get a sense of timing of data collection for WHIMS (and other cohorts) as well as overlap with other cohorts?

Ulrike Peters: Would it make sense try to expand ECCHO to more WHI participants in a new grant application given the richness of WHI and age?

Katie Stone: Thanks

andreazlacroix: Great overview Steve. Very helpful.

Aladdin Shadyab: Thanks - great presentation

**WHISPER Presentation: Laura Baker, [ldbaker@wakehealth.edu](mailto:ldbaker@wakehealth.edu)**

Aladdin Shadyab: Is WHISPER also adjudicating MCI and dementia? And are the cognitive tests similar to those of previous WHIMS studies?

lesleytinker: When conducting cog calls during covid-19, do participants want to talk more than usual?

Aladdin Shadyab: Thank you for your presentation, Laura.

JoAnn Manson: Are you asking about COVID diagnoses during contacts? Are you planning to use oximetry data for COVID-19 studies? (Such as whether pre-infection status predicts development of more severe disease?). Or longterm outcomes from COVID? Unique opportunity.

Laura Baker: We are asking about COVID diagnoses during contact. Yes, great opportunity. Great idea to look at relationship between oximetry and COVID. Our numbers may be small for those affected by COVID - most are at locked down at home. But, we can take a look.

**Poster Presentations:**

**Jonathan Fix: [jonathan\\_fix@med.unc.edu](mailto:jonathan_fix@med.unc.edu)**

01:18:55 cyndi thomson: How valid and reliable is self-reported vaccination?

01:22:15 cyndi thomson: were there differences for rural vs urban residency?

Garnet: Do you have a sense of what level of vaccination is needed to establish "herd immunity" for these particular infectious diseases?

Emily Gower: FYI Jonathan successfully passed his oral proposal defense for his PhD yesterday!

Kamal Masaki: Congratulations Jonathan!

Iris Leng: congratulations Jonathan!

rwild: Congratulations!

Roberta Ray: Congratulations Jonathan!

**Kate Hayden:** [khayden@wakehealth.edu](mailto:khayden@wakehealth.edu)

Bernhard Haring: Do you think that TET2 is driven by Inflammation - incident CVD over time ?

**Iris Leng:** [ileng@wakehealth.edu](mailto:ileng@wakehealth.edu)

cyndi thomson: Did you evaluate alcohol either as exposure or covariate?

lesleytinker: Iris — how did you compute/estimate complex carb?

lesleytinker: Tricky as self-report energy intake (and protein) tends to be systematically biased with overweight/obese more likely to underreport. Something to consider in your conclusions

Mike LaMonte: Have you verified that the CoDA and ilr transformation gave a more accurate solution than would standard scoring of the nutrient factors?

Sylvia Smoller: are you able to look at artificial sweeteners?

Iris Leng: Leslie, and Mike thanks for the good questions/suggestions! Definitely will consider them.

**Laura Baker/Margaret Scales:** [ldbaker@wakehealth.edu](mailto:ldbaker@wakehealth.edu), [mlscales@wakehealth.edu](mailto:mlscales@wakehealth.edu)

cyndi thomson: Are you planning to publish this methodological research? would be valuable as we may increasingly use non-clinic-based approaches for our research

susan: How will you deal with study-related initiated treatments on outcome assessments?

Ulrike Peters: Were you able to assess how many women followed up with their doctors if they had an indication of severe sleep apnea ?

**Chrisandra Shufelt:** [Chrisandra.shufelt@cshs.org](mailto:Chrisandra.shufelt@cshs.org)

cyndi thomson: How might these results inform on clinical guidelines in this area? how should those with family history of breast or ovarian cancer interpret these results?

Garnet: Death rates in women between age 42 and 63 are low so that seems an unlikely explanation for this discrepancy. Are there other differences that should be noted?

Kamal Masaki: Thank you! This was a great session and I enjoyed all the presentations.

Nora F: great session!

lesleytinker: Absolutely fantastic webinar! Thank you to all presenters and moderators and host!

cyndi thomson: Thank you to all the wonderful presenters- great session!

mvitolin: Wonderful wonderful session, thank you!

Chris: Thank you all, this was great!